
|Videos|November 15, 2020
AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
Author(s)OTE Staff Reports
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
2
AAO 2026: BRUNELLO 1-year results for remigromig in DME
3
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
4
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
5


















